Its up 0.18% from 10.35M shares previously. Flexion Therapeutics accounts for 1.3% of Gilder Gagnon Howe & Co. The overall volume in the last trading session was 1.84 million shares. Accuray Incorporated (NASDAQ:ARAY) has declined 21.41% since February 15, 2017 and is downtrending. It has outperformed by 52.56% the S&P500.
Cymabay Therapeutics, Inc.'s insider ownership stands at 0.4 percent, while its insider transaction is -85.25 percent. (NASDAQ:CBAY), so far this year is at +4.30.
The stock has Return on Assets (ROA) of -38.1 percent. After $-0.21 actual EPS reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10 % EPS growth. CBAY saw its productive stir of 7.68% in last week. As of February 22, 2017, it had 126 stations in 28 markets. It has outperformed by 48.71% the S&P500.
Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.52, from 1.74 in 2017Q2. When analyzing at performance throughout recent 6 months we have seen that Cymabay Therapeutics, Inc. Flexion Therapeutics earned a news impact score of 0.21 on Accern's scale. (NASDAQ:FLXN). 18,264 were accumulated by Metropolitan Life Insurance Communication. Goldman Sachs Grp Incorporated holds 203,237 shares or 0% of its portfolio.
Eastern Bank increased Guggenheim (BSCN) stake by 37,345 shares to 508,024 valued at $10.72M in 2017Q3. (NASDAQ:FLXN) for 456,384 shares. Lakeview Capital Prns Ltd Company holds 0.3% or 4,264 shares. Citadel Advsr Lc invested 0% in Flexion Therapeutics, Inc. The company has 44.95 Million shares outstanding and 43.47 Million shares were floated in market. (NASDAQ:FLXN) for 54,002 shares. It also reduced its holding in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 97,000 shares in the quarter, leaving it with 258,667 shares, and cut its stake in Bluebird Bio Inc (NASDAQ:BLUE). Alliancebernstein L P, a New York-based fund reported 32,100 shares. Investors mark this stock "active" as it exchanged hands with 1,308,856 shares contrast to its average daily volume of 719.11K shares. (NYSE:RSG) or 14,116 shares.
Equities researchers at Evercore ISI Group initiated coverage CymaBay Therapeutics (NASDAQ:CBAY) shares in a report shared with investors and clients on Tuesday, 13 February, IR.net reports. Therefore 88% are positive. Flexion Therapeutics had 22 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was initiated by Roth Capital with "Buy" on Thursday, January 25.
For this year, Flexion Therapeutics, Inc.
Consequently Cymabay Therapeutics (NASDAQ:CBAY)'s weekly and monthly volatility is 9.13%, 7.25% respectively. (NYSE:ETM) has "Buy" rating given on Monday, November 27 by Noble Financial. The firm has "Neutral" rating by H.C. Wainwright given on Wednesday, June 1. That puts the market capitalization at $914.43 mln. (NASDAQ:CBAY) rating on Monday, July 17. H.C. Wainwright upgraded the shares of CBAY in report on Monday, January 30 to "Buy" rating. The stock of Cymabay Therapeutics, Inc. The company has market cap of $748.53 million. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. A negative earnings surprise will usually result in a decline in share price. It is positive, as 13 investors sold ARAY shares while 26 reduced holdings. Kentucky Retirement Sys holds 0.07% in Republic Services, Inc. Lau Lc owns 13,079 shares. Kingdon Capital Management L.L.C. owns 883,321 shares or 1.39% of their U.S. portfolio. Kennedy Cap Mngmt Inc has invested 0.06% in Pioneer Power Solutions, Inc. As a serious shareholder, you need to look at plentiful factors that can assist you determine whether any given stock is a good investment. 110 were reported by Morgan Stanley. Macquarie Group Limited stated it has 8,275 shares. Carl Domino holds 0.06% in Accuray Incorporated (NASDAQ:ARAY) or 11,862 shares. Dafna Capital Management Llc bought 415,933 shares as the company's stock rose 21.05% with the market. (NYSE:RSG). First Fin In holds 0.11% or 2,500 shares in its portfolio. Davidson And Garrard stated it has 2.37% in AbbVie Inc. It operates in two divisions, Transmission & Distribution Solutions and Critical Power Solutions.
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.